Jeremy Ramdial

What is Measurable Residual Disease #MRD❓ 🟰 Hidden part of the iceberg ❄️ 👀 Minimal disease left behind leading to disease relapse 🤕 💊 New strategies available to treat MRD and cure #Leukemia 👊 #bloodcancer #cancerawareness #endcancer

Congrats Rohtesh Mehta!! of @MDAndersonNews on Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide jamanetwork.com/journals/jamao…

Dr. Garcia-Manero and @DrHKantarjian discuss the VERONA trial at #SOHO2025. Stay tuned for more at SOHO Insider

Dr. Uday Popat @SOHO25 . HCT still has an important role to play #mdssm

Dr Uday Popat presenting data on the role of SCT for patients with Int and High risk MDS. #MPNsm #MDS #SOHO2025 @MDAndersonNews

Please stop by poster CT 654 tonite at 6:30pm to discuss with Dr @dr_PrakhyathS his meta-analysis comparing two Cellular therapy options for patients with #MMsm . #SOHO2025 @SocietyofHemOnc

🔬 HCT in MDS – Holistic Decision Process (SOHO 2025) 🧩 Decision factors: •⚰️ Mortality •🏥 Morbidity •🧬 Prognosis •🧑‍⚕️ Patient views •🎂 Age & comorbidities •🧑‍🤝‍🧑 Donor availability 📊 Key insights (IPSS-M based): •Early transplant benefits Moderate-high, High, and Very High risk MDS patients. •Age matters → younger (<55y) benefit most, but even 55–65y group shows survival advantage. •Some Low/Moderate-low risk may benefit if: •Progressive cytopenias •Transfusion dependence •Failure of HMA ⚠️ Limitations: retrospective data, need for prospective validation. #MDS #BMT #Transplant #IPSSM #soho25

Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results and Research Summary: nej.md/4oT6aSg

Out in @Ajhematology: Relapse mechanisms after frontline FLT3 inhibitor therapy in FLT3 #AML include FLT3 loss and emergent non-FLT3 mutations. Post-relapse outcomes are poor, especially in FLT3 mut relapses. @NicholasShortMD #Leukemia doi.org/10.1002/ajh.70… #leusm

Survival of adult #ALL is significantly better 👍 ‼️ Ph ➖ ALL: Adding antibodies & immunotherapy is crucial, in frontline & salvage ‼️ Ph➕ ALL: Chemotherapy-free approach improves survival & spares transplant #leusm @DrHKantarjian @SocietyofHemOnc @OncoAlert

We're proud to support @lcalsfeld for LLS Visionary of the Year! ❤️ A true advocate for the cancer community, Clark is making a difference—and there’s still time to support his campaign before June 14! Donate here: tinyurl.com/calsfeld #CancerAdvocacy #VisionaryOfTheYear

Familiar face on Houston’s highways 🛣️ @lab_rezvani @MDAndersonNews

Please check out our paper published today in Nature that identifies CREM as a key checkpoint limiting CAR NK cell function.CRISPR knockout of CREM significantly enhanced anti-tumor activity, implicating a broader role in NK cell regulation. Huge congrats to @hindrafei and our

🧵1/ T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓. 📄Link: nature.com/articles/s4158… I’m so thrilled🥳to share our work out now🚨@Nature identifying🔎CREM as a central intracellular checkpoint🚦in #CARNK cells. Let me tell you a story...👇🏼

Discussing the latest updates in Chronic Myeloid Leukemia #CML at HemOnc Pulse meeting ✅ Looking for ways to improve #patient outcomes & access to treatment ✅ Panel discussion & insights on next steps in the field ✅ Connecting with colleagues & friends #HOPlive25 #leusm

@ASCO @Jeremy_Ramdial @JessSonMD @ShannonWestin Dr. @Jeremy_Ramdial shared details of a Phase II study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies that began enrolling in December 2024. @ASCO #ASCO25 #EndCancer

Was very excited to see all the interest in our off-the-shelf NK cell therapy given in combination with Allogeneic stem cell transplant for patients with high-risk AML. For many patients this was their second SCT and many others had TP53 mutated. Indicating high risk. #ASH24 #AML

The all-oral combination of revumenib with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) results in high remission rates in patients with relapsed/refractory AML with certain genetic mutations, our Dr. @GhayasIssa reported. #ASH24 #EndCancer

CONGRESS | #ASH24 | PRESENTATION @GhayasIssa @MDAndersonNews presents results from the phase I/II SAVE trial of revumenib plus ASTX727 and venetoclax in pediatric and adult patients with R/R AML. This all-oral regimen demonstrated high response rates, with an ORR of 82%, and an acceptable safety profile in heavily pretreated patients with R/R KMT2Ar, NPM1 mutated, or NUP98r AML. Follow our live feed for more updates: aml-hub.com/medical-inform… #leusm #AMLsm #MedicalCongress

@MeeraMohanMD @HadidiSamer @UAMSMyeloma @rajshekharucms @MansiShahMD @nishi_shah_ Thank you Dr Mohan!

@Jeremy_Ramdial @HadidiSamer @UAMSMyeloma @rajshekharucms @MansiShahMD @nishi_shah_ It was the standard 400mg/dl q4w on majority of patients

#ASH24 #mmsm Oral myeloma: Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study Our work @UAMSMyeloma @MeeraMohanMD @rajshekharucms @MansiShahMD @nishi_shah_ Patients characteristics and infections